India's biotechnology sector has emerged as a global innovation powerhouse, expanding from $10 billion in 2015 to $165 billion in 2024, and is projected to reach $300 billion by 2030[1]. This rapid growth has been propelled by strong government support, a robust network of research institutes, and a thriving startup ecosystem. India continues to lead in vaccine production, biosimilars, biologics, and emerging areas such as nutraceuticals and stem cell therapy, reflecting the remarkable India Biotech Industry Growth.
For investors, top Biotech Clusters in India combine world-class infrastructure, talent, and policy support, offering high-potential Biotech Investment Opportunities. These clusters are at the forefront of innovation, supporting both domestic healthcare needs and global markets.
Here are five major Biotech Hubs in India, strengthening India's position as an emerging biopharma powerhouse:
1. Genome Valley, Hyderabad — India’s Vaccine and Biopharma Hub
Genome Valley in Hyderabad is India's premier biotech cluster, often called the “Vaccine Hub of India.” It hosts leading domestic companies such as Bharat Biotech, Dr Reddy’s, and Aurobindo Pharma, alongside multinational R&D centres including DuPont, Sanofi, and Nektar Therapeutics. The cluster specialises in vaccine production, biologics, cell and gene therapies, and advanced research areas such as organoids and tissue engineering.
The cluster offers several advantages, including access to a large, highly skilled workforce in biotechnology and pharmaceuticals. The Telangana government supports infrastructure development under its Bio-Cluster Policy, offering government incentives for biotech startups such as tax incentives, subsidised land for R&D and manufacturing, and integration with super-speciality hospitals for clinical trials that meet multinational standards. Telangana has set an ambitious target of attracting ₹1 lakh crore in new investments in the life sciences sector by 2030, supported by employment for five lakh professionals under the “Roadmap 2030” vision, aiming to position Telangana as a global life sciences hub.
Recent developments further highlight Genome Valley's potential. The Serum Institute of India has established a Centre of Excellence to address future pandemics, while Biocon Biologics has launched biosimilars for the global market. Aurigene Pharmaceutical Services has set up a $40 million facility for R&D and manufacturing of therapeutic proteins, antibodies and viral vectors, reinforcing the cluster's industrial capabilities[2]. According to the Global Life Sciences Atlas 2025 report published by CBRE, Hyderabad ranks among the top global life sciences clusters[3]. Combining research excellence with large-scale manufacturing, Genome Valley remains a preferred choice for investors seeking high-impact biopharma innovations.
2. Mumbai–Pune corridor
The Mumbai–Pune corridor is one of India's most advanced life sciences ecosystems, where world-class pharmaceutical manufacturing meets fast-growing biotech innovation. Maharashtra contributes nearly 25–30% of India's pharmaceutical output and hosts over 40% of the nation's pharma R&D centres, with the corridor serving as its strategic nucleus.
While Mumbai and the Mumbai Metropolitan Region house leading global and domestic players such as Sun Pharma, Cipla, Pfizer, and GSK, Pune has emerged as the region's innovation engine. The city and its adjoining industrial zones, including Pimpri-Chinchwad and Hinjawadi, host a dense network of biotech firms, CRAMS leaders, and cutting-edge research institutions such as the National Chemical Laboratory and the Serum Institute of India. The TCG International Biotech Park (TCGIBP), India's first and largest integrated biotech park, anchors the corridor, offering an 80-acre hub for R&D and manufacturing in biotechnology and life sciences[5].
This ecosystem is strengthened by Maharashtra's progressive industrial policies, offering incentives such as stamp duty waivers, electricity duty exemptions, interest subsidies, and a dedicated Megaproject Policy to attract large-scale life sciences investments.
3. Ahmedabad–Vadodara cluster
One of India's most mature life sciences clusters, the Ahmedabad–Vadodara corridor integrates large-scale pharmaceutical manufacturing with an expanding biotech research ecosystem. The Ahmedabad pharma cluster hosts over 100 bulk drug producers and nearly 400 manufacturing units spanning allopathic and ayurvedic formulations, excipients, medical disposables, and specialised products.[6] It is home to leading industry players including Zydus Cadila, Sun Pharma, Torrent, Alembic, Dishman, Intas, and the Sarabhai group.
Strong linkages between SMEs, industrial associations, financial institutions, and research bodies have created a cohesive ecosystem, making Ahmedabad one of India’s most developed pharma hubs. Complementing this strength, the state government is developing a 700-acre Biotechnology Park at Savli in Vadodara through GSBTM and GIDC.[7] Designed as a public–private venture, the park aims to provide specialised infrastructure, accelerate commercialisation, foster industry partnerships, and boost biotech innovation across the state.
4. Electronic City, Bengaluru — Biotech meets technology
India’s IT capital, Bengaluru, is expanding its technology leadership into biotechnology. Bengaluru’s Electronic City hosts over 1,300 biotech startups and companies, including Biocon and Syngene. The cluster merges pharmaceutical research with digital solutions, including healthtech, AI-driven drug discovery, and contract research services, showcasing biotech investment opportunities in tech-integrated pharma.
The city’s biotech cluster offers significant investment advantages, including opportunities in biosimilars, APIs, vaccines, and nutraceuticals. Bengaluru’s IT-biotech convergence facilitates rapid commercialisation and innovation, while investors also benefit from access to venture capital and global partnerships in biotechnology and healthcare technology.
The city’s robust supporting infrastructure and skilled talent pool further increase its attractiveness. Bengaluru houses premier institutions such as the Indian Institute of Science (IISc) and the Jawaharlal Nehru Centre for Advanced Scientific Research, which produce highly skilled professionals. Furthermore, startup accelerators and incubators, including NASSCOM’s 10,000 Startups programme and BIRAC funding for startups, bolster Bengaluru’s innovation ecosystem. With this technology-focused approach, Bengaluru is well-suited for investors aiming to combine digital innovation with biopharma research.
5. Taramani, Chennai — Southern biotech and pharma innovation
Chennai’s Taramani cluster is a leading biotech and pharmaceutical hub in southern India, specialising in biologics, biosimilars, and medical research. Its proximity to premier academic institutions such as Anna University, IIT Madras, and Madras University fosters strong industry-academia collaboration, enabling cutting-edge research and innovation.
The cluster offers several investment advantages. Incentives under Tamil Nadu’s Biotech Policy include capital subsidies, tax rebates, and support for R&D infrastructure[8]. Investors also benefit from Chennai’s well-established pharmaceutical and clinical research ecosystem, which supports both domestic manufacturing and export-focused activities. The city’s emphasis on innovation in biosimilars, generics, and precision medicine further enhances its attractiveness.
Recent developments highlight Taramani’s growing prominence. Increasing investments in biosimilars and contract research have broadened Chennai’s global presence, while partnerships between local start-ups and multinational pharmaceutical firms promote knowledge exchange and technological progress. With robust research facilities and established manufacturing infrastructure, Taramani is emerging as an appealing destination for investors seeking innovation and growth in southern India.
Conclusion
India’s leading biotech clusters provide investors with a diverse ecosystem of research, manufacturing, and commercialisation opportunities. Genome Valley anchors Hyderabad’s exceptional vaccine and biomanufacturing capabilities, while Bengaluru combines technology with biotech innovation. In Western India, the Mumbai–Pune corridor and the Ahmedabad–Vadodara belt demonstrate strong research depth and industrial manufacturing leadership. Meanwhile, the Translational Health Science and Technology Institute (THSTI) in Faridabad is strengthening India’s biomedical research landscape by advancing translational research to develop vaccines, diagnostics, and therapeutics for major public health challenges. Biotech investments in India are set to accelerate, driven by an increasing emphasis on scale, innovation, and advanced life sciences research.
Supported by government schemes for biotech sector like Bio-E3 and Bio-RIDE, FDI-friendly policies and a growing talent pool and startup ecosystem, these clusters position India as a global hub for biotechnology investment. The Research and Development in India (RDI) Scheme, with an outlay of ₹1 lakh crore, identifies biotechnology as one of its key sunrise sectors.[9] By 2030, India’s bioeconomy is expected to reach $300 billion, presenting significant opportunities for investors in vaccines, biologics, biosimilars, stem cell therapy, and digital biotech solutions.[10]
Investing in these clusters supports India’s goal of cementing its position as the “Pharmacy of the World,” ensuring access to innovation-led growth, skilled talent, and a world-class regulatory ecosystem.
This listicle is written by Anand Prasad
